PORTFOLIO NEWS Nurix Therapeutics Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares April 16, 2024 Read More » ORIC Pharmaceuticals Announces First Patients Dosed Across Three Expansion Cohorts in Phase 1b Trial of ORIC-114 in Patients with Mutated NSCLC April 15, 2024 Read More » Neurona Therapeutics Presents Positive Clinical Update from NRTX-1001 Cell Therapy Trial in Adults with Drug-resistant Focal Epilepsy at American Academy of Neurology (AAN) 2024 Annual Meeting April 15, 2024 Read More » Nurix Therapeutics Reports First Quarter Fiscal 2024 Financial Results and Provides a Corporate Update April 10, 2024 Read More » RAPT Therapeutics Announces Promising Results From Phase 2 Trial of Tivumecirnon in Combination with Anti-PD-1 Immunotherapy In CPI-Experienced Head and Neck Cancer Patients April 9, 2024 Read More » Synthekine Presents Positive Initial Results from Phase 1a/1b Clinical Trial of α/β Biased IL-2, STK-012, for Treatment of Advanced Solid Tumors April 9, 2024 Read More » Nurix Therapeutics Reports First Clinical Evidence of CNS Activity of NX-5948, a Brain-Penetrant, Orally Available, BTK Degrader in Development for B Cell Malignancies April 9, 2024 Read More » Nurix Therapeutics Announces Extension of Strategic Collaboration with Sanofi to Develop Novel Targeted Protein Degraders of STAT6 April 9, 2024 Read More » Accent Therapeutics Presents Data Supporting Two Lead Programs at AACR 2024 Annual Meeting April 8, 2024 Read More » ORIC Pharmaceuticals Presents Preclinical Data on Two Programs at the 2024 American Association for Cancer Research (AACR) Annual Meeting April 8, 2024 Read More » « Previous Page1 Page2 Page3 Page4 Page5 Page6 Page7 Page8 Page9 Page10 Page11 Page12 Page13 Page14 Page15 Page16 Page17 Page18 Page19 Page20 Next »
Nurix Therapeutics Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares April 16, 2024 Read More »
ORIC Pharmaceuticals Announces First Patients Dosed Across Three Expansion Cohorts in Phase 1b Trial of ORIC-114 in Patients with Mutated NSCLC April 15, 2024 Read More »
Neurona Therapeutics Presents Positive Clinical Update from NRTX-1001 Cell Therapy Trial in Adults with Drug-resistant Focal Epilepsy at American Academy of Neurology (AAN) 2024 Annual Meeting April 15, 2024 Read More »
Nurix Therapeutics Reports First Quarter Fiscal 2024 Financial Results and Provides a Corporate Update April 10, 2024 Read More »
RAPT Therapeutics Announces Promising Results From Phase 2 Trial of Tivumecirnon in Combination with Anti-PD-1 Immunotherapy In CPI-Experienced Head and Neck Cancer Patients April 9, 2024 Read More »
Synthekine Presents Positive Initial Results from Phase 1a/1b Clinical Trial of α/β Biased IL-2, STK-012, for Treatment of Advanced Solid Tumors April 9, 2024 Read More »
Nurix Therapeutics Reports First Clinical Evidence of CNS Activity of NX-5948, a Brain-Penetrant, Orally Available, BTK Degrader in Development for B Cell Malignancies April 9, 2024 Read More »
Nurix Therapeutics Announces Extension of Strategic Collaboration with Sanofi to Develop Novel Targeted Protein Degraders of STAT6 April 9, 2024 Read More »
Accent Therapeutics Presents Data Supporting Two Lead Programs at AACR 2024 Annual Meeting April 8, 2024 Read More »
ORIC Pharmaceuticals Presents Preclinical Data on Two Programs at the 2024 American Association for Cancer Research (AACR) Annual Meeting April 8, 2024 Read More »
